Jeito Capital co-leads eur 65 million (USD 71 MILLION) financing in Corteria Pharmaceuticals, a French Biopharmaceutical company

Jeito Capital
  • Jeito Capital co-leads oversubscribed financing
  • Corteria, a late preclinical stage company, is developing first-in-class therapies with promising novel approaches for unaddressed heart failure subpopulations, addressing high unmet medical needs
  • Jeito Capital marks its first investment in the cardiovascular space, further diversifying its strong portfolio

Paris, France, September 7th 2023 – Jeito Capital (“Jeito”), a global leading investment firm dedicated to healthcare and biopharma, announced today that it is co-leading a EUR 65m (USD 71m[1]) Series A financing round in Corteria Pharmaceuticals (“Corteria” or the “Company”), a biopharmaceutical company specialized in the development of transformative therapies for unaddressed heart failure subpopulations.

The oversubscribed financing was co-led by new investors Jeito and Orbimed, with participation from existing investors Kurma Partners, Fountain Healthcare Partners, V-Bio Ventures, Invivo Capital, and Omnes Capital.

Corteria was founded in 2021 by Sanofi’s former head of cardiovascular research, Philip Janiak and Marie-Laure Ozoux, former cardiovascular project leader at Sanofi, around two cardiovascular programs in-licensed from Sanofi[2].

Proceeds from the financing will be used to advance the Company’s heart failure pipeline into the clinic.

Since its inception, Corteria’s pipeline has expanded rapidly and comprises today three first-in-class therapies:

  • A once-daily subcutaneous CRF2[3] agonist for the treatment of Worsening Heart Failure. It is anticipated that Corteria will bring this lead asset, into clinical trials to validate the treatment pathway in early 2024.
  • A once-monthly subcutaneous CRF2[3] agonist, specifically developed for Right Heart Failure treatment. This compound also holds potential for broader applications in chronic cardiometabolic diseases, particularly those with coexisting conditions such as obesity and sarcopenia.
  • An AVP (arginine vasopressin) neutralizing monoclonal antibody for the treatment of Acute Heart Failure with Hyponatremia.

Jeito Capital has partnered with Corteria Pharmaceuticals, reflecting its vision to champion promising French and European biopharma companies with the potential to become global market leaders especially in Europe and the US. This collaboration marks Jeito’s first investment in the cardiovascular space, where emerging innovations and a supportive regulatory environment offer transformative potential for patient outcomes. Andreas Wallnoefer, Partner at Jeito Capital and with strong industry experience in the cardiovascular field, will join Corteria’s Board of Directors.

Dr. Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital, commented: “With our first investment in the cardiovascular field, we are partnering with Corteria Pharmaceuticals, a French company with a global vision to address well-defined sub-populations of heart failure, with an urgent need for new and effective treatments. Corteria’s strong pipeline of assets, backed by a dedicated and highly experienced team with a proven track record in cardiovascular development, represents an exciting opportunity to expand treatment options. Their commitment to transformative therapies as a leading French biopharma with global aspirations perfectly aligns with Jeito’s mission, and we see great potential to make a meaningful difference in patient lives.”

Andreas Wallnoefer, Partner at Jeito Capital added: “Despite current treatments, heart failure is a progressing disease that impacts severely the lives of many patients and remains one of the leading causes of mortality worldwide. Corteria focuses on translating important therapeutic innovations in cardiology into clinical practice. Our investment in Corteria reflects Jeito’s commitment to address significant unmet needs in the realm of cardiology. We are excited to join forces with Corteria’s dedicated team to develop a portfolio of medicines with important clinical benefits for patients.”

“This financing marks a major milestone in our mission to bring therapies to heart failure subpopulations with high unmet needs,” said Philip Janiak, Founder and CEO of Corteria Pharmaceuticals. “We are extremely grateful to Jeito and OrbiMed as our new investors for their trust in our science and team and to our existing investors for their support and commitment since inception. We are looking forward to working all together to develop next generation transformative therapeutics.”

About Jeito Capital

Jeito Capital is a global leading Private Equity company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access globally, especially in Europe and the United States. Jeito Capital has €534 million under management and a rapidly growing portfolio of investments. Jeito Capital is based in Paris with a presence in Europe and the United States.

For more information, please visit or follow us on Twitter or LinkedIn.

About Corteria Pharmaceuticals

Founded in 2021, Corteria Pharmaceuticals is a privately held biopharmaceutical company developing first-in-class drugs in heart failure subpopulations. Despite some improvements in the management of this serious disease, the prevalence of heart failure keeps increasing with more than 60 million patients worldwide. Corteria’s strategy implies innovative patient stratification and target selection based on human evidence and a better understanding of the disease biology in patients with a focus on worsening and acute heart failure and right heart failure.

More information available at:

[1] Applying an 1.0886 EUR/USD exchange rate as of 30 August 2023 (Banque de France) rounded to $71m

[2] CRF2 peptide agonist and AVP neutralizing monoclonal antibody programs

[3] Corticotropin-releasing hormone receptor 2

For further information please contact:

Jeito Capital
Rafaèle Tordjman
Assia Mouhout, EA
Tel: +33 6 76 49 37 94

Consilium Strategic Communications
Mary-Jane Elliott /
Davide Salvi / Kris Lam
Tél. : +44 (0) 20 3709 5700 

Categories: News


Verisian secures £1M to accelerate drug time to market


Despite significant technological innovation in computational biology and drug development over the past decades, it still takes 10-15 years to take a drug to market, with over 90% failure rate. One of the main bottlenecks lies in the long duration required for the analysis and submission of clinical trial data.

This is why we are excited to back Verisian, a UK-based startup on a mission to increase the rate at which human health improves by redefining clinical trial analysis and drug approvals. It aims to build out the largest medical code repository by parsing and virtualising study code from clinical trials.

Co-founded by experienced technologists Tomás Sabat Stöfsel (CEO, previously COO/Founding Team Member of Vaticle, the creators of the open source database TypeDB) and Henning Kuich (CTO, previously Senior Computational Scientist at Bayer Pharmaceuticals), the company is building products that empower researchers and regulators to analyze and monitor studies transparently in real-time, leading to improved and safer therapies for devastating diseases.

Tomas Sabat Stöfsel, CEO and co-founder of Verisian comments:

“It’s crazy that to this day, after clinical trials finish and the science is done, it still takes months to years before a drug is available to patients. We believe it should be immediate. That’s why we’re building the infrastructure and tools that change how we analyse clinical trials, leading to faster and better drug submissions in the pharmaceutical industry.”

Henning Kuich, CTO and co-founder, adds:

“Clinical trials are and will remain the bottleneck for advancing human health. They are expensive, take a long time, and are absolutely necessary. They alone ensure efficacy and safety of any health-related product. So the rate at which public health improves is directly correlated with the speed and quality of clinical trials and their analysis. This is what Verisian is all about: increasing the rate at which human health improves.”

Oliver Wirtz, Head of Analysis Standards & Reporting Quality, Bayer and a product development partner emphasises:

“The technology Verisian uses is new and revolutionary: parsing study code and leveraging that is exactly the right way to know what really happened in a study.”

Claire Springett, Statistical Programmer, AstraZeneca, another product development partner adds:

“Verisian is exactly what the pharmaceutical industry has been waiting for, easy traceability of programs and CDISC mappings which will streamline clinical trials for the future.”

On why we invested in Verisian, our partner Tom Wilson comments:

“Even with huge advancements in the space and innovations across the value chain, it still takes too long to bring drugs to market. One of the primary bottlenecks is around clinical trials and managing the huge amounts of data required to obtain the necessary regulatory approvals. We see huge potential for Verisian’s platform to  improve the speed, clarity, and reliability of clinical data reporting and in so doing accelerate the time it takes to get drugs to market. Tomas and Henning are the perfect founders to be building this with their ideal combination of relevant startup, technical and domain experience and we’re delighted to have the opportunity to partner with them to lead this first round of funding”

We are excited to lead Verisian’s first funding round, alongside Superseed, Recode Health, Magnetic, and angel investors Paul Forster, Will Neale, Endre Sagi, Naud van der Ven, Loic Veillard Garoz, and Sudhamma Lee. With the fresh funding the company is planning to grow their engineering team; build a first version of their “builder”, to enable pharma to program studies ready for submission; and establish and grow their initial design partnerships with tier-1 pharmaceuticals.

For more information, visit

Categories: News


NextGen Healthcare Enters into Definitive Agreement to Be Acquired by Thoma Bravo


NextGen Healthcare Shareholders to Receive $23.95 Per Share in Cash, a 46.4% Premium to Unaffected Stock Price

Transaction to Accelerate NextGen Healthcare’s Growth and Innovation as the Trusted Advisor to Healthcare Providers

REMOTE-FIRST COMPANY/NEW YORKNextGen Healthcare, Inc. (Nasdaq: NXGN) (“NextGen Healthcare” or the “Company”), a leading provider of innovative, cloud-based healthcare technology solutions, today announced that it has entered into a definitive agreement to be acquired by Thoma Bravo, a leading software investment firm. Upon completion of the transaction, NextGen Healthcare will become a privately held company.

Under the terms of the agreement, NextGen Healthcare shareholders will receive $23.95 per share in cash. The per share purchase price represents a 46.4% premium to the Company’s unaffected closing stock price on August 22 (the last trading day prior to published market speculation regarding a potential transaction involving the Company) and a 39.2% premium to the 30-day volume-weighted average price for the period ending September 1.

“Under the terms of the agreement, NextGen Healthcare shareholders will receive significant immediate cash value for their shares. In addition, with Thoma Bravo as a partner, the Company will benefit from increased capital, expertise and strategic flexibility to accelerate the Company’s leadership in providing healthcare technology solutions,” said David Sides, President and Chief Executive Officer of NextGen Healthcare. “Thoma Bravo has a 20+ year record of investing in premier companies in the software and technology sectors. We look forward to joining forces to deliver on our mission of Better Healthcare Outcomes for All.”

Jeffrey H. Margolis, Chair of the NextGen Healthcare Board of Directors, added, “The agreement with Thoma Bravo validates NextGen Healthcare’s substantial strength and follows interest in the Company by many parties. It is the result of a deliberate process to maximize shareholder value and best position NextGen Healthcare for continued growth and success. The agreement delivers significant cash value to our shareholders and creates exciting opportunities for NextGen Healthcare’s employees and clients.”

“NextGen Healthcare’s mission-critical EMR software and surround solutions are the backbone of ambulatory practices across the United States,” said A.J. Rohde, a Senior Partner at Thoma Bravo. “We are so proud to be working with NextGen Healthcare in its next phase as a private company and look forward to continued product innovation to better support NextGen Healthcare’s thousands of highly-valued customers.”

“We have followed NextGen Healthcare’s impressive business transformation for many years and are excited to apply Thoma Bravo’s strategic and operational expertise to drive continued growth and innovation,” said Peter Hernandez, a Vice President at Thoma Bravo. “We look forward to partnering with the NextGen Healthcare team to further accelerate product investments to better support the increasingly complex needs of ambulatory providers and ultimately improve patient outcomes.”

Transaction Details

The transaction, which was approved unanimously by the NextGen Healthcare Board of Directors, is expected to close in the fourth calendar quarter of 2023, subject to customary closing conditions, including approval by NextGen Healthcare shareholders and the receipt of required regulatory approvals. The transaction is not subject to a financing condition.

Upon completion of the transaction, NextGen Healthcare’s common stock will no longer be listed on any public stock exchange.


Morgan Stanley & Co. LLC is acting as financial advisor to NextGen Healthcare, and Latham & Watkins LLP is acting as legal advisor.

William Blair & Company is acting as financial advisor to Thoma Bravo, and Goodwin Procter LLP is acting as legal advisor.

About NextGen Healthcare, Inc.

NextGen Healthcare, Inc. (Nasdaq: NXGN) is a leading provider of innovative healthcare technology solutions. We are reimagining ambulatory healthcare with award-winning solutions that enable high-performing practices to create healthier communities. We partner with medical, behavioral and oral health providers in their journey toward whole person health and value-based care. Our highly integrated, intelligent and interoperable solutions go beyond EHR and Practice Management to increase clinical quality and productivity, enrich the patient experience and drive superior financial performance. We are on a quest to achieve better healthcare outcomes for all. Learn more at, and follow us on FacebookTwitterLinkedInYouTube, and Instagram.

About Thoma Bravo

Thoma Bravo is one of the largest software investors in the world, with more than US$131 billion in assets under management as of June 30, 2023. Through its private equity, growth equity and credit strategies, the firm invests in growth-oriented, innovative companies operating in the software and technology sectors. Leveraging Thoma Bravo’s deep sector expertise and strategic and operational capabilities, the firm collaborates with its portfolio companies to implement operating best practices and drive growth initiatives. Over the past 20 years, the firm has acquired or invested in more than 440 companies representing over US$250 billion in enterprise value (including control and non-control investments). The firm has offices in Chicago, London, Miami, New York and San Francisco. For more information, visit Thoma Bravo’s website at

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements in this press release include, but are not limited to, statements regarding the consummation of the proposed merger between the Company and affiliates of Thoma Bravo (the “Merger”). These forward-looking statements involve a number of risks and uncertainties that could cause actual results to differ materially from those indicated in such forward-looking statements, including but not limited to the ability of the parties to consummate the proposed Merger and the possibility that various closing conditions for the proposed Merger may not be satisfied or waived, and the ability to realize the benefits expected from the proposed Merger. The forward-looking statements in this press release are based on information available to the Company as of the date hereof, and the Company disclaims any obligation to update any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. For additional information regarding forward-looking statements, please refer to discussions under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in our most recent Annual Report on Form 10-K and in our other reports filed with the U.S. Securities and Exchange Commission (the “SEC”). The Company’s SEC filings are available on the Investor Relations section of our website at and on the SEC’s website at

The following factors, among others, could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements: (i) the proposed Merger may not be completed in a timely manner or at all, including the risk that any required regulatory approvals are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the Company or the expected benefits of the proposed Merger or that the approval of the Company’s stockholders is not obtained; (ii) the failure to realize the anticipated benefits of the proposed Merger; (iii) the possibility that competing offers or acquisition proposals for the Company will be made; (iv) the possibility that any or all of the various conditions to the consummation of the proposed Merger may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals); (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the proposed Merger, including in circumstances which would require the Company to pay a termination fee or other expenses; (vi) the effect of the announcement or pendency of the proposed Merger on the Company’s ability to retain and hire key personnel, or its operating results and business generally; (vii) significant transaction costs associated with the Merger; (viii) potential litigation relating to the Merger; (ix) the risk that disruptions from the Merger will harm the Company’s business, including current plans and operations; (x) legislative, regulatory and economic developments affecting the Company’s business; and (xi) general economic and market developments and conditions; (xii) the evolving legal, regulatory and tax regimes under which the Company operates; and (xiii) potential business uncertainty, including changes to existing business relationships, during the pendency of the Merger that could affect the Company’s financial performance.

Additional Information

This press release may be deemed solicitation material in respect of the proposed acquisition of the Company. A special stockholder meeting will be announced soon to obtain stockholder approval in connection with the proposed Merger. The Company expects to file with the SEC a proxy statement and other relevant documents in connection with the proposed Merger. Investors of the Company are urged to read the definitive proxy statement and other relevant materials carefully and in their entirety when they become available because they will contain important information about the Company and the proposed Merger. Investors may obtain a free copy of these materials (when they are available) and other documents filed by the Company with the SEC at the SEC’s website at and at the Company’s website at

Participants in the Solicitation

The Company and its directors, executive officers and certain other members of management and employees may be deemed to be participants in soliciting proxies from its stockholders in connection with the proposed Merger. Information regarding the persons who may, under the rules of the SEC, be considered to be participants in the solicitation of the Company’s stockholders in connection with the proposed Merger will be set forth in the Company’s definitive proxy statement for its special stockholder meeting. Additional information regarding these individuals and any direct or indirect interests they may have in the proposed Merger will be set forth in the definitive proxy statement when and if it is filed with the SEC in connection with the proposed Merger.

Read the release on the Business Wire website here.

Categories: News


Thompson Street Capital Partners Portfolio Company Transnetyx Expands Offering Through Acquisition of Laragen


Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, today announced the acquisition of Laragen by Transnetyx, a global leader in outsourced genetic services and a TSCP portfolio company. The addition of Laragen’s offerings to the Transnetyx solution suite improves access to genetic testing services for leading research institutes around the world, while supporting the Transnetyx mission to ensure researchers have the most efficient path to discovery. Terms of the transaction were not disclosed.

“Laragen is a perfect fit for Transnetyx,” stated Bob Bean, CEO of Transnetyx. “Our highly accurate, automated testing solutions and cohesive distribution network will allow us to provide researchers unparalleled access to Laragen’s enhanced sequencing services.”

Laragen provides sequencing, genotyping, and other laboratory services for genomics research to leading government, pharmaceutical, and academic research institutes. Transnetyx and Laragen have both served researchers for more than two decades.

“Thompson Street is excited to partner with Laragen to expand its offerings and support its mission of providing researchers with the tools needed to accelerate their discovery,” said Bob Dunn, Managing Partner at TSCP and a member of the Transnetyx Board of Directors. “We look forward to continuing to execute against their long-term plan for growth as they continue this important work.”

Categories: News


Bergman Clinics opens a new clinic in Rijswijk with a focus on eye care

NPM Capital

Bergman Clinics has opened a new focus clinic in Rijswijk. The new location offers the best possible eye care as a result of our ultimately modern complex with advanced equipment and facilities. The care provided here can be fully reimbursed by your health insurer, providing this is medically indicated and following a referral by your GP.

The opening of this modern, state-of-the-art location has enabled Bergman Clinics to respond to a growing demand for top quality, client-focussed treatments for plannable medical care. The specialisation Bergman Clinics is known for allows for very efficient working methods. This subsequently reduces access times and means more clients can be seen at an earlier stage.

The new location offers specialist treatments for a variety of eye diseases and conditions, including cataracts, glaucoma and macular degeneration. Clients can rely on a multidisciplinary approach, whereby experienced ophthalmologists work together with optometrists to realise the best possible care results. Cataract surgery is by far the most common procedure. Bergman Clinics | Rijswijk is expected to be able to help around 4000 clients get rid of their cataract problems every year.

The focus clinic has a brand new class 2 operating room at its disposal, especially designed for ophthalmic operations. The clinic also boasts twelve optimally equipped consulting rooms, allowing us to assist a large number of clients.

Dr Flora Berkhout is an Ophthalmologist at Bergman Clinics. She is very enthusiastic about the new focus clinic: “It’s hugely beneficial to form part of such a large ophthalmic organisation. We have gained an incredible amount of experience with eye care and how to organise this as optimally as possible in our other Bergman Clinics locations. I have personally worked at several Bergman Clinics locations: Ede, Den Bosch and Amsterdam. We can individually adopt each and every one of these best practices. Plus it’s certainly also going to be a very nice location. Fantastic for both our clients and our employees. Setting up this focus clinic together with the team is going to be a very exciting challenge to rise to!” according to Dr Berkhout.

Expansion of several care programmes later on this year
The new focus clinic will also be introducing other specialisms later on this year, in addition to ophthalmic care, including Skin & Vessels (dermatology & proctology), Woman (gynaecology) and ENT (ear, nose and throat). This will allow Bergman Clinics to offer an extensive care programme, making sure clients in Rijswijk and the surrounding area have access to top quality medical treatments in a variety of different areas.


Categories: News


Nordic Capital-backed EDG embarks on transformative step via the separation and sale of its European laboratory business

Nordic Capital

European Dental Group (“EDG” or the “Company”), a leading pan-European oral care services platform, has announced a significant, transformative milestone on its journey. After rapidly growing its European clinics platform while in parallel establishing a European laboratory business, the Company has decided to separate and sell its laboratory activities (including Excent, Flemming, Artinorway Group), which will be acquired by Oakley Capital (“Oakley”) in the Transaction.

“Under EDG stewardship, we’ve built one of the leading dental laboratory players in Europe,” said Toby Anderson, CEO of EDG.

“Following an internal strategic review, we identified considerable benefits of separating our clinic and dental laboratory activities and believe that the separation will optimise the future growth of both.”

This strategic decision allows EDG to solely focus its resources on continuing the rapid development of its leading oral care clinic networks in the Netherlands, Germany, the UK, France, Switzerland, and Belgium. Its commitment to providing best-in-class oral care to patients and being the preferred partner for clinicians and staff remains at the centre of EDG’s mission.

EDG’s dental clinics will maintain a close partnership with the departing dental laboratories, preserving an ongoing collaboration that has contributed significantly to joint success.

The transaction’s completion remains subject to regulatory approval.

For more information, please contact:
Christoph Mosebach
Deputy Head of BD and M&A
tel: +31 627845159

About European Dental Group
Founded in 2018 by Nordic Capital via the acquisitions of Dental Clinics and TopOrtho in the Netherlands, Flemming dental labs and a small dental chain in Germany and Adent in Switzerland, the European Dental Group is a leading European dental care and services provider that relies on quality leadership, a strong team concept and well-established processes.

Categories: News


£3.1mn investment in leading digital health platform Mable Therapy

Gresham House

We are pleased to announce a £3.1 million investment into Mable Therapy, the UK’s leading digital health platform for children’s speech and language therapy and counselling services.

The business addresses a significant and growing area of need – 1.4mn children in the UK have long-term speech, language or communication needs and one in five children aged 5-16 have a diagnosed mental health problem.

Founded by Martha Currie and Elliot Agró in 2015, Mable provides easy access to a nationwide network of therapists who deliver live, 1-2-1 sessions through a bespoke online platform that facilitates improved therapeutic outcomes in a child-friendly environment.

Mable offers an affordable direct-to-consumer service, as well as solutions for the education and healthcare sectors, where technology adoption is now seen as vital to address the growing unmet demand.

In the last year alone, Mable has delivered over 22,000 hours of therapy to over 3,000 children.

As part of the investment, Gresham House Ventures has supported the appointment of Oli White as Mable’s CEO, bringing significant commercial expertise in the health and education technology sectors, most recently as Chief Commercial Officer at Doc Abode. Education business leader, Andrea Carr, will also join Mable as independent Chair.

The investment, led by Benjamin Faulkner and Tom Makey, follows several recent investments in the healthcare and education sectors.

In April 2023, Gresham House Ventures invested £4.0mn into neuro-inclusion solutions provider Cognassist, whose software platform supports individuals with hidden learning needs across education and the workplace. This followed a £4.5mn investment in September 2022 in Orri, a specialist clinic for the treatment of eating disorders. The investment in Mable represents the fourth new investment by Gresham House Ventures in 2023.

Mable Therapy was advised on the transaction by Zuleika Salter and James Balicki at finnCap Group.

Benjamin Faulkner, Associate Director at Gresham House Ventures said:

“Mable’s technology transforms the lives of children in their crucial early stages of development. There is significant growth potential for Mable within the wider education and health sectors where its technology offering can drive meaningful efficiencies for public service providers. Martha and Elliot have built an excellent business that is backed by a wealth of clinical and technological expertise, and we are confident that Mable can continue to revolutionise the provision of this vital support across the UK.”

Co-founders, Martha Currie and Elliot Agró said:

“Mable’s mission has always been to design therapy that puts children at its core, giving them the best chance to reach their full potential. Our pioneering technology has already helped thousands of families across the UK, and with this investment by Gresham House Ventures we can take this support even further. The investment will facilitate the development of an intra-therapy app designed to engage and empower children beyond session hours, and school screening tools to help educators in assessing students’ mental health and speech and language needs. We also look forward to welcoming to the team Oli and Andrea, whose expertise will be instrumental as we continue to enhance and expand our service beyond the UK.”

Oli White, Chief Executive said:

“This investment will enable us to extend our reach in the sectors where our technology is already helping schools and other care providers to support children facing complex challenges. With Gresham House Ventures’ outstanding track record of working with businesses in this sector, Mable is well-positioned to accelerate its growth trajectory in the coming years.”

Categories: News


Oakley Capital invests in Flemming Dental, Excent and Artinorway Group

No Comments

Oakley Capital (“Oakley”), a leading pan-European private equity investor, is pleased to announce that Oakley Capital Fund V (“Fund V”) has agreed to acquire Flemming Dental, Excent, and Artinorway Group (combined as the “Company”) in a carve-out from European Dental Group (“EDG”), a leading pan-European oral care and services provider, to form one of the leading dental laboratories groups in Europe. 

The Company provides a comprehensive range of services, including the design and manufacture of dental prostheses (crowns, bridges and dentures) and orthodontics (braces, retainers and aligners), utilising technology including CAD software, computer-aided milling and 3D printing, as well as local craftmanship. The Company currently services c.5,000 clinics across nearly 70 dental laboratories throughout Europe.


The Company currently services c.5,000 clinics across nearly 70 dental laboratories throughout Europe.

Liberty 2

Oakley will work closely with the management to establish Flemming Dental, Excent and Artinorway Group as an independent business and to become a leader in the global dental lab market. Through this transaction, Oakley is leveraging its network of entrepreneurs, partnering with Hidde Hoeve, the co-founder of Excent Tandtechniek, a group of dental laboratories acquired by EDG in 2018. The collaboration between Oakley and the Company’s experienced management team will see the execution of an ambitious growth strategy, driven by organic growth, international expansion and targeted M&A.

Fund V’s investment

Through Fund V’s investment, the Company will benefit from Oakley’s extensive expertise in digitalisation, helping the Company to capitalise on technological innovation in the dental lab industry and the rapid digital transformation of the market. Fund V’s investment will enable Flemming Dental, Excent and Artinorway Group to accelerate innovation and the adoption of cutting-edge technology, providing solutions with unparalleled precision for dental clinics and their patients across Europe and beyond. The European dental lab market is large and growing with strong customer stickiness, valued at approximately €10 billion today, and is also highly fragmented offering compelling opportunities for value creation through buy-and-build, which is an area Oakley has extensive expertise in.

In Oakley we have the ideal partner to support Flemming Dental, Excent and Artinorway Group as they begin the next chapter as an independent business. We are well positioned to capitalise on the accelerating digitalisation of dental laboratories. Together with the current management we will maintain focus on our clients, local craftsmanship and innovation. Oakley’s expertise will be invaluable as we execute our growth strategy to become the leader in the global dental lab market.

Hidde Hoeve

Excent Co-founder and CEO of the new combined entity

Oakley was advised by Paul Hastings, PwC, LEK and KPMG in connection with this transaction.

Quote Peter Dubens

This is a key inflection point for the dental laboratory industry, with rapid digitalisation poised to revolutionise dental design and manufacturing, and patient care. We look forward to working closely with Hidde Hoeve and the management team as we establish Flemming Dental, Excent and Artinorway Group as an independent company and leverage transformational new technologies to unlock its full potential for future growth.

Peter Dubens

Managing Partner and co-Founder — Oakley Capital

Categories: News


Nordic Capital-backed Prospitalia Group becomes Vivecti Group, Dr. Benjamin I. Behar appointed as new CEO

Nordic Capital

Prospitalia Group has appointed Dr. Benjamin I. Behar as new CEO and will operate under the new brand Vivecti Group.

Prospitalia Group, a leading purchasing service company in the German healthcare market, today announced the appointment of Dr. Benjamin I. Behar as new Group CEO. As lever, catalysator and reliable partner, the companies of the group will in future provide their expertise to healthcare providers and other market participants under the new brand Vivecti Group. The new Group brand reflects the evolved and integrated approach to serve clients as a full service partner for all key challenges in hospitals and adjacent fields.

Dr. Benjamin I. Behar brings a particularly deep understanding of the challenges and management of hospitals. Before joining Vivecti Group, he played a significant role in establishing one of the fastest-growing hospital groups, Artemed SE. From the founding stage of Artemed with three hospitals to a nationally operating hospital group with 18 high-performance hospitals, he was responsible for both, the restructuring and integration of the new hospitals, as well as for purchasing and communications. Prior to that, he worked for McKinsey & Company, advising hospital operators such as Vivantes, the University Medical Center Mainz, and the Klinikverbund Südwest.

“Being the catalyst that helps healthcare providers and other market participants operate more effectively is an immensely fulfilling mission for me, as economic efficiency is the fundamental premise for medical quality, ultimately benefiting the patients. Economic efficiency and medical quality are not contradictory but mutually reinforcing. That’s why the Vivecti Group provides our partners with a comprehensive and integrated range of services and products, enhancing their performance unlike any other corporate group,” said Dr. Benjamin I. Behar.


Press contacts: 

For Vivecti Group:
Beilquadrat GmbH I Agentur für Identität und Identifikation
Tel +49 40 8821532-22

About Vivecti Group

As a lever, catalyst and reliable partner, the Vivecti Group, under the leadership of Dr. Benjamin Behar, is the performance partner for healthcare facilities. Founded in 2015 with 450 employees and an annual turnover of 120 million euros over the past five years, the company originally originated from a purchasing group for hospitals founded in 1993. Today, Prospitalia, Pro Care Management, Wawibox, Miralytik, Prospitalia h-trak as well as the companies of WMC and the Hospital Management Group (HMG) belong to the Vivecti Group and thus cover an unparalleled range of products and services in the German market. In this way, healthcare providers are comprehensively supported strategically and operationally in the areas of purchasing and material cost optimisation, digital products and data analytics as well as managed services and consulting – with the aim of helping healthcare facilities to gain new strengths in times of transformation of the entire system. For more information, please visit:

Categories: News


Alantra Private Equity portfolio company Health in Code acquires Genologica


With this acquisition Health in Code achieves its goal of doubling its size in three years

  • This is Health in Code’s first acquisition since 2020 when it was created through the merger of three leading companies in the clinical genetics sector in Spain: Imegen, Genycell Biotech, and Health in Code
  • Since 2020, Health in Code has delivered organic annual growth of more than 20%
  • Health in Code’s expansion plans include the acquisition of other genomic diagnostics companies in Spain and the rest of Europe

Health in Code, a leading clinical genetic diagnostics company in Spain and an Alantra Private Equity portfolio company, has acquired genetic analysis laboratory Genologica to consolidate its leading position in Spain. Both parties have agreed not to disclose financial details of the transaction.

Founded in Malaga and with a strong presence in Andalusia, Genologica has more than 15 years of experience in genetic analysis for the prevention, diagnosis, assessment, and treatment of hereditary or genetic diseases. Its founders and main executives, Javier, José María and Daniel Porta, will continue to lead Genologica and will join Health in Code’s management team.

Health in Code is the result of the merger of three leading companies in the clinical genetics sector in Spain at the beginning of 2020: Imegen, Genycell Biotech and Health in Code. Alantra Private Equity is the majority shareholder of the Group, which includes among its shareholders the founding partners of the three former companies.

The acquisition of Genologica is the Group’s first add-on since its foundation and is in line with a buy-and-build strategy targeting companies or projects characterized by differentiation and clinical excellence.

Health in Code expects to reach €45m in revenues this year, of which approximately €4m will be contributed by Genologica. This represents an annual growth rate of more than 20% since 2020, doubling the initial size of the Group and demonstrating the sector’s strong growth.

The Group’s expansion plans include the acquisition of other medical genetics companies to complement its portfolio of services and products, as well as the organic development of new international markets based on a differential value proposition and unique technological capabilities. Health in Code currently has operational centers in Valencia, where it is headquartered, La Coruña, Granada and Malaga, employing more than 200 professionals. Last June, Health in Code installed the first NovaSeq X Plus in Spain, reaffirming its position as a leader in sequencing committed to whole genome studies.

Categories: News